Stock listing
ALNFL Stock Price, News, Filings & Events — Nfl Biosciences Sa
Selected listing: ALNFL · EURONEXT · EUR · FR
This page tracks Nfl Biosciences Sa's ALNFL:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ALNFL:EURONEXT. ALNFL:EURONEXT is the stock-level entry point for investors researching Nfl Biosciences Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nfl Biosciences Sa is a public company listed on the French market under the ticker ALNFL. The company has a market capitalization of approximately 12.14 million euros. Nfl Biosciences focuses on developing innovative solutions in the biosciences sector.
- Ticker
- ALNFL:EURONEXT
- Asset type
- Stock
- Market cap
- $12.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- EURONEXT
- Currency
- EUR
Nfl Biosciences Sa ALNFL:EURONEXT stock context
This page tracks Nfl Biosciences Sa's ALNFL:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ALNFL:EURONEXT. ALNFL:EURONEXT is the stock-level entry point for investors researching Nfl Biosciences Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nfl Biosciences Sa is a public company listed on the French market under the ticker ALNFL. The company has a market capitalization of approximately 12.14 million euros. Nfl Biosciences focuses on developing innovative solutions in the biosciences sector.
Latest news from Nfl Biosciences Sa
NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tab...
September 8, 2026
NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation
July 28, 2026
International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral ...
July 7, 2026
NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain
June 30, 2026
NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
June 1, 2026
Research Nfl Biosciences Sa
Nfl Biosciences Sa investor report
Review AI stock analysis and investor report context for ALNFL:EURONEXT.
Nfl Biosciences Sa company profile
View the public company page for Nfl Biosciences Sa on 6ix.
Nfl Biosciences Sa news
Read company news and market updates connected to Nfl Biosciences Sa.
Nfl Biosciences Sa investor events
Find investor webinars, events, and replay context for Nfl Biosciences Sa.
Alternate listings
A3CTQ0:LSX
DE · EUR
Alternate listing for Nfl Biosciences Sa; the primary context on this page is ALNFL:EURONEXT.
A3CTQ0:LS
DE · EUR
Alternate listing for Nfl Biosciences Sa; the primary context on this page is ALNFL:EURONEXT.
82F:FWB
DE · EUR
Alternate listing for Nfl Biosciences Sa; the primary context on this page is ALNFL:EURONEXT.
82F:SWB
DE · EUR
Alternate listing for Nfl Biosciences Sa; the primary context on this page is ALNFL:EURONEXT.